IL240418B - Biologically active molecules, their conjugates and therapeutic uses - Google Patents

Biologically active molecules, their conjugates and therapeutic uses

Info

Publication number
IL240418B
IL240418B IL240418A IL24041815A IL240418B IL 240418 B IL240418 B IL 240418B IL 240418 A IL240418 A IL 240418A IL 24041815 A IL24041815 A IL 24041815A IL 240418 B IL240418 B IL 240418B
Authority
IL
Israel
Prior art keywords
conjugates
biologically active
therapeutic uses
active molecules
molecules
Prior art date
Application number
IL240418A
Other languages
English (en)
Hebrew (he)
Other versions
IL240418A0 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL240418A0 publication Critical patent/IL240418A0/en
Publication of IL240418B publication Critical patent/IL240418B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D507/00—Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D505/00; Such ring systems being further condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL240418A 2013-03-15 2015-08-06 Biologically active molecules, their conjugates and therapeutic uses IL240418B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792216P 2013-03-15 2013-03-15
PCT/US2014/029757 WO2014145090A1 (en) 2013-03-15 2014-03-14 Biologically active molecules, conjugates thereof, and therapeutic uses

Publications (2)

Publication Number Publication Date
IL240418A0 IL240418A0 (en) 2015-09-24
IL240418B true IL240418B (en) 2020-11-30

Family

ID=50933481

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240418A IL240418B (en) 2013-03-15 2015-08-06 Biologically active molecules, their conjugates and therapeutic uses

Country Status (19)

Country Link
US (3) US10570151B2 (enExample)
EP (2) EP3964237A1 (enExample)
JP (3) JP6847388B2 (enExample)
KR (1) KR102306490B1 (enExample)
CN (1) CN105188766B (enExample)
AU (1) AU2014233385C1 (enExample)
BR (1) BR112015022585B1 (enExample)
CA (1) CA2902872A1 (enExample)
CL (1) CL2015002765A1 (enExample)
EA (1) EA038512B1 (enExample)
ES (1) ES2996807T3 (enExample)
IL (1) IL240418B (enExample)
MA (1) MA38496B2 (enExample)
MX (1) MX379256B (enExample)
MY (1) MY183572A (enExample)
PH (1) PH12015502131B1 (enExample)
SG (1) SG11201507481WA (enExample)
WO (1) WO2014145090A1 (enExample)
ZA (1) ZA201505813B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8542802B2 (en) 2007-02-15 2013-09-24 Global Tel*Link Corporation System and method for three-way call detection
MY169117A (en) 2012-12-21 2019-02-18 Bioalliance Cv Hydrophilic self-immolative linkers and conjugates thereof
JP6847388B2 (ja) 2013-03-15 2021-03-31 レゲネロン ファーマシューティカルス，インコーポレーテッド 生物活性分子、そのコンジュゲート、及び治療用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
CN105530942B (zh) 2013-08-26 2019-10-11 瑞泽恩制药公司 一种包含大环内酯类非对映体的药物组合物、其制备方法和用途
PT3126388T (pt) 2014-03-11 2019-08-20 Regeneron Pharma Anticorpos anti-egfrviii e suas utilizações
CN106573074B (zh) 2014-06-02 2022-04-12 里珍纳龙药品有限公司 生物活性分子偶联物、试剂和制备方法及其治疗用途
AU2015276821A1 (en) 2014-06-20 2017-01-12 Abgenomics International Inc. Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof
EA034950B1 (ru) * 2015-03-27 2020-04-09 Регенерон Фармасьютикалз, Инк. Производные майтанзиноида, их конъюгаты и способы использования
EP3308801A4 (en) 2015-06-09 2019-02-27 XDCExplorer (Shanghai) Co., Ltd. ANTIBODY-ACTIVE CONJUGATE, INTERMEDIATE PRODUCT, METHOD OF MANUFACTURE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3319994B1 (en) 2015-07-06 2024-02-07 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
MX395252B (es) 2016-01-08 2025-03-25 Altrubio Inc Anticuerpos tetravalentes anti ligando-1 de glicoproteina p-selectina (psgl-1) y usos de estos.
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
EP3515945A1 (en) 2016-09-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
SI3515487T1 (sl) 2016-09-23 2023-09-29 Regeneron Pharmaceuticals, Inc. Bispecifična protitelesa proti-MUC16-CD3 in konjugati zdravil proti-MUC16
TWI782930B (zh) * 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
JP7174699B2 (ja) 2016-11-29 2022-11-17 レゲネロン ファーマシューティカルス，インコーポレーテッド Ｐｒｌｒ陽性乳癌の治療方法
KR20240172236A (ko) 2017-01-06 2024-12-09 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
JP7181181B2 (ja) 2017-02-28 2022-11-30 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
JP7364471B2 (ja) 2017-05-18 2023-10-18 レゲネロン ファーマシューティカルス，インコーポレーテッド シクロデキストリンタンパク質薬物コンジュゲート
KR102760654B1 (ko) 2017-06-07 2025-02-04 리제너론 파마슈티칼스 인코포레이티드 효소 내재화를 위한 조성물 및 방법
TWI804499B (zh) 2017-06-23 2023-06-11 美商維洛斯生物公司 Ror1抗體免疫接合物
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
AU2018346507B2 (en) 2017-10-04 2025-03-13 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
AU2018365946B2 (en) 2017-11-07 2025-08-28 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
MX2020005860A (es) 2017-12-06 2020-09-09 Avidity Biosciences Inc Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica.
US12037411B2 (en) 2018-04-30 2024-07-16 Regeneron Pharmaceuticals, Inc. Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof
AU2019269685B2 (en) 2018-05-17 2025-12-04 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
KR20210061995A (ko) * 2018-06-26 2021-05-28 이뮤노젠 아이엔씨 Adam9를 표적으로 하는 면역콘쥬게이트 및 이를 이용하는 방법들
JPWO2020059772A1 (ja) 2018-09-20 2021-08-30 第一三共株式会社 抗ｈｅｒ３抗体−薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
TW202043288A (zh) * 2019-01-07 2020-12-01 日商安斯泰來製藥股份有限公司 包含配位子及ＣＥＡＣＡＭ５抗體Ｆａｂ片段之複合體
CN113727757A (zh) 2019-02-21 2021-11-30 瑞泽恩制药公司 使用结合met的抗-met抗体和双特异性抗原结合分子治疗眼癌的方法
WO2020219820A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
US11578090B2 (en) 2019-06-06 2023-02-14 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
WO2020247818A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Una amidites and uses thereof
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
IL294989A (en) 2020-01-24 2022-09-01 Regeneron Pharma Conjugated protein-antiviral compounds
AU2021228225A1 (en) 2020-02-28 2022-09-01 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind HER2, and methods of use thereof
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
JP7748962B2 (ja) 2020-03-27 2025-10-03 アビディティー バイオサイエンシーズ，インク． 筋ジストロフィーを処置するための組成物および方法
US11701427B2 (en) 2020-04-16 2023-07-18 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
WO2022014698A1 (ja) 2020-07-17 2022-01-20 第一三共株式会社 抗体－薬物コンジュゲートの製造方法
WO2022087243A1 (en) 2020-10-22 2022-04-28 Regeneron Pharmaceuticals, Inc. Anti-fgfr2 antibodies and methods of use thereof
CA3198294A1 (en) 2020-11-10 2022-05-19 Thomas Nittoli Selenium antibody conjugates
TW202300178A (zh) 2021-03-18 2023-01-01 美商西根公司 內化的生物活性化合物偶聯物選擇性釋放藥物
US20240191272A1 (en) 2021-03-31 2024-06-13 Microbiopharm Japan Co., Ltd. Method for producing antibody-drug conjugate and enzyme used for the same
AU2022255573A1 (en) 2021-04-05 2023-11-23 Alhena Science S.R.L. Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens
MX2024003266A (es) 2021-09-16 2024-04-03 Avidity Biosciences Inc Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
JP2025503504A (ja) 2021-12-23 2025-02-04 マイリキュール，インコーポレイテッド ポリヌクレオチドの送達のための組成物
JP2025511758A (ja) 2022-04-05 2025-04-16 アルテイア サイエンス エッセ．エッレ．エッレ． 新規腫瘍特異的抗原を標的とする骨髄性障害および急性白血病の処置
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
CN119072327A (zh) 2022-04-07 2024-12-03 双亥生命科学株式会社 新型基于肽的免疫抗癌剂
IL318625A (en) 2022-07-29 2025-03-01 Regeneron Pharma Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
TW202500135A (zh) 2023-06-02 2025-01-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物與rasg12c抑制劑之組合
US12491257B2 (en) 2023-06-27 2025-12-09 Avidity Biosciences, Inc. Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates
US12409230B2 (en) 2023-06-30 2025-09-09 Avidity Biosciences, Inc. Compositions comprising PLN-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP1258255A1 (en) 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
BR0308090A (pt) * 2002-03-01 2006-04-11 Univ Tulane conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20110250133A1 (en) 2003-01-13 2011-10-13 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2530285C (en) 2003-06-27 2019-12-24 Abgenix, Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
EP1747021B1 (en) 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Self-immolative linkers and drug conjugates
CA2587589A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
PT1819359E (pt) 2004-12-09 2015-05-28 Janssen Biotech Inc Imunoconjugados anti-integrina, métodos para a sua produção e sua utilização
KR101103108B1 (ko) * 2005-06-20 2012-01-04 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US20070160617A1 (en) 2005-06-20 2007-07-12 Psma Development Company, Llc PSMA antibody-drug conjugates
AU2006280146B2 (en) 2005-08-09 2012-06-28 Immunogen, Inc. Method of acylating maytansinol with chiral amino acids
NZ565964A (en) * 2005-08-24 2011-11-25 Immunogen Inc Process for preparing maytansinoid antibody conjugates by purifying with tangential flow filtration
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
DK2502938T3 (en) 2006-10-27 2015-04-20 Genentech Inc Antibodies and immunoconjugates and uses thereof
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
CN101687037B (zh) 2007-05-08 2013-07-10 健泰科生物技术公司 半胱氨酸改造的抗muc16抗体和抗体药物偶联物
EP3561513A1 (en) 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
EP2644204B1 (en) 2008-03-18 2017-04-19 Genentech, Inc. Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab
EP2276509B1 (en) * 2008-04-11 2016-06-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
NO2281006T3 (enExample) 2008-04-30 2017-12-30
DK2374481T3 (en) 2008-07-21 2016-02-01 Polytherics Ltd New reagents and methods for the conjugation of biological molecules
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
RU2587621C2 (ru) * 2009-04-01 2016-06-20 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2464974A1 (en) 2009-08-10 2012-06-20 UCL Business PLC Functionalisation of solid substrates
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
UY32913A (es) 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
JP2013506709A (ja) 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
PH12012500665B1 (en) * 2009-10-23 2019-10-30 Amgen British Columbia Anti-gcc antibody molecules and related compositions and methods
US8501692B2 (en) 2009-12-14 2013-08-06 The Regents Of The University Of Michigan Compositions and methods for altering cocaine esterase activity
TWI540136B (zh) 2010-04-15 2016-07-01 梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
WO2012005982A2 (en) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Reporter for rna polymerase ii termination
HUE031903T2 (en) 2010-08-02 2017-08-28 Regeneron Pharma Mice producing VL binding proteins
EA023205B9 (ru) 2010-09-01 2016-09-30 Байер Интеллектуэль Проперти Гмбх Амиды n-(тетразол-5-ил)- и n-(триазол-5-ил)арилкарбоновых кислот и гербицидное средство
JP5828902B2 (ja) 2010-10-29 2015-12-09 イミュノジェン， インコーポレイテッド 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
JP2013542958A (ja) 2010-11-03 2013-11-28 イミュノジェン・インコーポレーテッド アンサマイトシン誘導体を含む細胞傷害性剤
US20120121615A1 (en) * 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
AU2012257417B2 (en) 2011-05-16 2017-09-14 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
CN103702996A (zh) 2011-05-27 2014-04-02 Ambrx公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6209159B2 (ja) * 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
AU2012322933B2 (en) 2011-10-14 2017-02-02 Medimmune Limited Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
ES2660233T3 (es) 2011-10-14 2018-03-21 Seattle Genetics, Inc. Pirrolobenzodiazepinas y conjugados dirigidos
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
MX341523B (es) 2011-10-14 2016-08-24 Medimmune Ltd Pirrolobenzodiazepinas.
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CA2855746A1 (en) 2011-11-16 2013-05-23 John Stephen HILL Methods of treating epidermal growth factor deletion mutant viii related disorders
KR20140139480A (ko) 2011-12-05 2014-12-05 이제니카 바이오테라퓨틱스, 인크. 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
RU2015101333A (ru) 2012-06-19 2016-08-10 Политерикс Лимитед Новый способ получения конъюгатов антител и новые конъюгаты антител
HUE062385T2 (hu) * 2012-10-23 2023-10-28 Synaffix Bv Módosított antitest, antitest-konjugátum és eljárás ezek elõállítására
NO2789793T3 (enExample) 2012-10-24 2018-01-27
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CN104650113A (zh) 2012-12-21 2015-05-27 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
CN103254213B (zh) 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 类美登素酯的制备方法及用于所述方法的组合物
JP6847388B2 (ja) 2013-03-15 2021-03-31 レゲネロン ファーマシューティカルス，インコーポレーテッド 生物活性分子、そのコンジュゲート、及び治療用途
CN103254311B (zh) 2013-05-09 2015-05-13 齐鲁制药有限公司 一种制备抗体-美登素类生物碱药物偶联物的方法
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US10781259B2 (en) 2013-06-06 2020-09-22 Magenta Therapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
US20140363454A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
ES2891755T3 (es) 2013-06-06 2022-01-31 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
CN105530942B (zh) 2013-08-26 2019-10-11 瑞泽恩制药公司 一种包含大环内酯类非对映体的药物组合物、其制备方法和用途
WO2015081281A1 (en) 2013-11-26 2015-06-04 Segway Orthopaedics, Inc. Surgical blade with viewing aperture
KR102320019B1 (ko) 2013-11-27 2021-11-01 레드우드 바이오사이언스 인코포레이티드 히드라지닐-피롤로 화합물 및 콘쥬게이트 제조 방법
EP3077402B1 (en) 2013-12-02 2018-09-19 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
CN106573074B (zh) 2014-06-02 2022-04-12 里珍纳龙药品有限公司 生物活性分子偶联物、试剂和制备方法及其治疗用途
EA034950B1 (ru) 2015-03-27 2020-04-09 Регенерон Фармасьютикалз, Инк. Производные майтанзиноида, их конъюгаты и способы использования
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
EP3515945A1 (en) 2016-09-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof

Also Published As

Publication number Publication date
EA038512B1 (ru) 2021-09-08
CN105188766B (zh) 2019-07-12
US10570151B2 (en) 2020-02-25
PH12015502131B1 (en) 2022-03-23
US11345715B2 (en) 2022-05-31
SG11201507481WA (en) 2015-10-29
WO2014145090A1 (en) 2014-09-18
PH12015502131A1 (en) 2016-01-25
ZA201505813B (en) 2023-01-25
EA201500905A1 (ru) 2017-02-28
JP2019135239A (ja) 2019-08-15
EP3964237A1 (en) 2022-03-09
NZ710814A (en) 2020-10-30
JP6847388B2 (ja) 2021-03-31
JP2021105007A (ja) 2021-07-26
AU2014233385C1 (en) 2019-09-19
HK1212890A1 (en) 2016-06-24
US12378258B2 (en) 2025-08-05
ES2996807T3 (en) 2025-02-13
AU2014233385B2 (en) 2019-03-07
MX379256B (es) 2025-03-10
AU2014233385A1 (en) 2015-09-17
EP2968593B1 (en) 2024-11-20
US20220332729A1 (en) 2022-10-20
US20160030591A1 (en) 2016-02-04
CL2015002765A1 (es) 2016-06-24
EP2968593A1 (en) 2016-01-20
MA38496B2 (fr) 2021-01-29
MA38496A1 (fr) 2018-06-29
US20200277306A1 (en) 2020-09-03
BR112015022585A2 (pt) 2017-10-24
KR20150128932A (ko) 2015-11-18
MY183572A (en) 2021-02-26
IL240418A0 (en) 2015-09-24
CN105188766A (zh) 2015-12-23
CA2902872A1 (en) 2014-09-18
JP2016521256A (ja) 2016-07-21
BR112015022585B1 (pt) 2023-04-04
KR102306490B1 (ko) 2021-09-28
MX2015011348A (es) 2016-01-15

Similar Documents

Publication Publication Date Title
ZA201505813B (en) Biologically active molecules, conjugates thereof, and therapeutic uses
PL2958944T3 (pl) Koniugaty przeciwciało anty-DLL3-PBD i ich zastosowania
ZA201505735B (en) Cancer drug and uses
EP3049443A4 (en) Anti-trop-2 antibody-drug conjugates and uses thereof
EP2850059A4 (en) CONJUGATES OF MEDICATION, METHODS OF CONJUGATION AND USE THEREOF
EP2983670A4 (en) Ibrutinib combination therapy
PT2968552T (pt) Anticorpo dos agentes alvo, combinações e uso para os mesmos
IL241532B (en) Pyrrolobenzodiazepines and their conjugates
PL2986304T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
PL3082877T3 (pl) Cytotoksyczne peptydy i ich koniugaty
GB201317982D0 (en) Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) Pyrrolobenzodiazepines and conjugates thereof
SG11201508167PA (en) Therapeutic compositions and uses thereof
ZA201509307B (en) Pharmaceutical composition, preparation and uses thereof
EP2980817A4 (en) ELECTRODE-ACTIVE MATERIAL, ELECTRODE AND ELECTRICITY STORAGE DEVICE
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine
EP3010345A4 (en) Expanded therapeutic potential in nitroheteroaryl antimicrobials
TWI562776B (en) Pharmaceutical composition and uses thereof
EP3047834A4 (en) Drug supply body, and drug supply unit
EP3046556A4 (en) Combination drug therapy
HUE052236T2 (hu) Szerelvény gyógyszerbejuttató eszközhöz, valamint gyógyszerbejuttató eszköz
FR2967672B1 (fr) Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
GB201304038D0 (en) Treated cells and therapeutic uses
IL245983A0 (en) Biologically active insulin derivatives
EP3048886A4 (en) 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed